A Louisiana man has filed a new hernia mesh lawsuit alleging he suffered a toxic reaction following implantation of C.R. Bard Inc.’s Perfix mesh product.
Perfix mesh is a woven polypropylene mesh manufactured by C.R. Bard’s Davol, Inc. subsidiary. According to complaint filed in the U.S. District Court, Eastern District of Louisiana, on November 17th, Bruce Baptist was implanted with Perfix mesh during surgical hernia repair in November 2015. He subsequently suffered seriously complications, including pain and inflammation, that required additional surgery. (Case No. 2:17-cv-12718)
The hernia mesh lawsuit alleges that the polypropylene used to manufacture Perfix mesh is toxic once inserted into the human body. Following implantation, cells in the body attack the mesh as a foreign substance, resulting in injuries such as those experienced by Baptist.
Hernia mesh complications allegedly associated with C.R. Bard Perfix mesh include:
The complaint also claims that Perfix mesh is extremely difficult to remove from the body and that complete removal is difficult, if not impossible.
“Defendants knew or should have known that Perfix Mesh was not a safe and effective treatment for hernias. Defendants also knew or should have known that Perfix Mesh was considerably less effective and safe than other meshes or methods for hernia repair,” the lawsuit states. “Additionally, Defendants knew of should have known that Perfix Mesh was defective and likely to cause severe complications.”
This is just one of the most recent hernia mesh lawsuit filings to involve a C.R. Bard device. On October 19th, a woman from Pittsburgh, Pennsylvania, filed suit against Bard and Davol after she suffered bowel adhesions and other complications allegedly related to Marlex hernia mesh.
C.R. Bard has also been named a defendant in claims involving its Ventralight ST and Ventralex ST hernia mesh products.
Johnson & Johnson and its Ethicon, Inc. subsidiary are facing dozens of lawsuits involving Physiomesh Flexible Composite mesh, which was withdrawn from the market in March 2016 due to high rates of recurrence and revision. The majority of those claims have been centralized in a multidistrict litigation now underway in the U.S. District Court, Northern District of Georgia.
A multidistrict litigation has also been established in the U.S. District Court, District of New Hampshire, for injury claims involving Atrium Medical’s C-Qur hernia mesh implant.